Sagimet Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Six Months Ended June 30, | ||||||
| · · 2024 · · 2023 | ||||||
| Cash flows from operating activities: · · | ||||||
| Net loss | | $(14,747) | | $(13,372) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Accretion of discount on marketable securities, net | | (670) | | (39) | ||
| Non-cash lease expense | | 71 | | 68 | ||
| Stock-based compensation expense | | 2,208 | | 1,824 | ||
| Changes in operating assets and liabilities: | | | | |||
| Prepaid expenses and other current assets | | 1,048 | | 375 | ||
| Accounts payable and accrued liabilities | | 309 | | (1,589) | ||
| Operating lease liabilities | | (61) | | (71) | ||
| Net cash used in operating activities | | (11,842) | | (12,804) | ||
| Cash flows from investing activities: | | | ||||
| Purchases of marketable securities | | | (82,952) | | | — |
| Sales of marketable securities | | 10,795 | | 32,200 | ||
| Net cash provided by (used in) investing activities | | (72,157) | | 32,200 | ||
| Cash flows from financing activities: | | | ||||
| Proceeds from sale of Series A common stock, net of underwriter commissions and discounts | | | 105,750 | | | — |
| Proceeds from exercise of stock options | | 114 | | — | ||
| Payment of financing costs | | | (1,045) | | | (1,046) |
| Net cash provided by (used in) financing activities | | 104,819 | | (1,046) | ||
| Net increase in cash and cash equivalents | | 20,820 | | 18,350 | ||
| Cash and cash equivalents at beginning of period | | 75,139 | | 158 | ||
| Cash and cash equivalents at end of period | | $95,959 | | $18,508 | ||
| | | | | | | |
| Supplemental non-cash investing and financing activities: | | | | | | |
| Deferred financing costs included in accounts payable and accrued expenses | | $— | | $1,591 | ||
| Right-of-use assets obtained in exchange for operating lease obligations | | $149 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.